A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline-and taxane-pretreated patients with metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1345-1352

  Karachaliou, N ^a   Kouroussis, Ch ^a   Papakotoulas, P ^a   Kalbakis, K ^a   Tryfonidis, K ^a   Vardakis, N ^a   Poppis, E ^a   Georgoulias, V ^a   Mavroudis, D ^a,b  

^a Hellenic Oncology Research Group HORG   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Anthracycline; Docetaxel; Gemcitabine; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BREAST METASTASIS; CANCER MORTALITY; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HAND FOOT SYNDROME; HUMAN; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; BREAST TUMOR; CLINICAL TRIAL; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY; TAXOIDS; TREATMENT OUTCOME;

EID: 84862295816     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1824-z     Document Type: Article

References (31)

1. Moreno-Aspitia A, Perez EA (2009) Anthracycline-and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 31:1619-1640
2. Kornek GV, Haider K, Kwasny W, Raderer M, Schull B, Payrits T, Depisch D, Kovats E, Lang F, Scheithauer W (2002) Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8:1051-1056 (Pubitemid 34517639)
3. SEER (2011) Cancer Statistics Review 1975-2006. http://seercan cergov/csr/1975-2006. Assessed June 2009
4. Mavroudis D, Malamos N, Polyzos A, Kouroussis C, Christophilakis C, Varthalitis I, Androulakis N, Kalbakis K, Milaki G, Georgoulias V (2004) Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. Oncology 67:250-256 (Pubitemid 39551709)
5. Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399-3406 (Pubitemid 47310875)
6. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G (2000) A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82:529-534 (Pubitemid 30085185)
7. Amadori D, Cecconetto L (2006) Gemcitabine and taxanes in metastatic breast cancer. Ann Oncol 17(Suppl 5):v173-v176 (Pubitemid 43985230)
8. Silvestris N, D'Aprile M, Andreola G, Locopo N, Marini L, Crucitta E, De LM, Lorusso V (2004) Rationale for the use of gemcitabine in breast cancer (review). Int J Oncol 24:389-398
9. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN (2001) Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6:133-146 (Pubitemid 32323452)
10. Tomova A, Bartsch R, Brodowicz T, Tzekova V, Timcheva C, Wiltschke C, Gerges DA, Pawlega J, Spanik S, Inbar M, Zielinski CC (2010) Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracyclinepretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Res Treat 119:169-176
11. Alexopoulos A, Tryfonopoulos D, Karamouzis MV, Gerasimidis G, Karydas I, Kandilis K, Stavrakakis J, Stavrinides H, Georganta C, Ardavanis A, Rigatos G (2004) Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 15:95-99 (Pubitemid 38139609)
12. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Investig 8:147-159 (Pubitemid 20350387)
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10 (Pubitemid 19099520)
15. Kaplan EL, Meier P (1959) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
16. Jassem J, Carroll C, Ward SE, Simpson E, Hind D (2009) The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer 45:2749-2758
17. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roche HH (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217 (Pubitemid 350232252)
18. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914-923
19. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803 (Pubitemid 46657376)
20. Sanchez-Rovira P, Gonzalez E (1999) Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer. Breast Cancer Res Treat 57:87
21. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950-3957
22. Palmeri S, Vaglica M, Spada S, Filippelli G, Farris A, Palmeri L, Massidda B, Misino A, Ferrau F, Comella G, Leonardi V, Condemi G, Mangiameli A, De CG, Macaluso MC, Cajozzo M, Iannitto E, Danova M (2005) Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology 68:438-445 (Pubitemid 41160975)
23. Laufman LR, Spiridonidis CH, Pritchard J, Roach R, Zangmeister J, Larrimer N, Moore T, Segal M, Jones J, Patel T, Gutterman L, Carman L, Colborn D, Kuebler JP (2001) Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 12:1259-1264 (Pubitemid 32994754)
24. Mavroudis D, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E, Potamianou A, Kosmas C, Rigatos G, Giannakakis T, Kalbakis K, Apostolaki F, Vlachonicolis J, Kakolyris S, Samonis G, Georgoulias V (1999) Salvage chemotherapy in anthracyclinepretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 10:211-215 (Pubitemid 29113182)
25. Chan S, Friedrichs K, Noel D, Pinter T, Van BS, Vorobiof D, Duarte R, Gil GM, Bodrogi I, Murray E, Yelle L, von MG, Korec S, Simmonds P, Buzzi F, Gonzalez MR, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin inpatients with metastatic breast cancer. J Clin Oncol 17:2341-2354 (Pubitemid 29368232)
26. Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du BA, Kreienberg R, Mayordomo JI, Anton A, Harrison M, Jones A, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753-1760
27. Yardley DA (2010) Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer 10:64-73
28. Schroder CP, de ML, Westermann AM, Smit WM, Creemers GJ, de GH, Stouthard JM, van DG, Erjavec Z, van BA, Vader W, Willemse PH (2011) Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel. Eur J Cancer 47:1355-1362
29. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365 (Pubitemid 39295024)
30. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671 (Pubitemid 351549913)
31. Murialdo R, Bertolotti F, Pastorino G, Mencoboni M, Bergaglio M, Folco U, Cinzia N, Vaira F, Simoni C, Canobbio L, Parodi M, Brema F, Ballestrero A (2011) Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial. Cancer Chemother Pharmacol 68:1009-1016